May 10, 2017 / 11:14 AM / in 2 months

BRIEF-Bristol-Myers Squibb, Calithera Biosciences expand collaboration

1 Min Read

May 10 (Reuters) - Bristol-myers Squibb Co

* Bristol-Myers Squibb and Calithera Biosciences expand collaboration evaluating opdivo (nivolumab) in combination with CB-839 into non-small cell lung cancer and melanoma

* Calithera Biosciences Inc - study to evaluate potential of CB-839 plus opdivo to target immunosuppressive cancer metabolism in tumor microenvironment Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below